Pipex Pharmaceuticals' Oral Flupirtine Receives IRB Approval to Initiate Phase II Clinical Trial for Fibromyalgia

Published: Oct 07, 2008

ANN ARBOR, Mich., Oct. 7, 2008 (GLOBE NEWSWIRE) -- Pipex Pharmaceuticals, Inc. (AMEX:PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system and autoimmune diseases, today announced that its double-blind, randomized, placebo-controlled phase II clinical trial of oral flupirtine for the treatment of fibromyalgia has received ethics committee approval to initiate the clinical trial.

Back to news